	US 12,064,455 B2
	Free fatty acids and methods of manufacture and use for treating coronavirus and other viral respiratory infections
Einar Stefansson, Reykjavik (IS); and Thorsteinn Loftsson, Reykjavik (IS)
Assigned to LIPID PHARMACEUTICALS EHF, Reykjavik (IS)
Filed by LIPID PHARMACEUTICALS EHF, Reykjavik (IS)
Filed on Mar. 18, 2021, as Appl. No. 17/206,041.
Claims priority of provisional application 63/073,757, filed on Sep. 2, 2020.
Claims priority of provisional application 62/991,368, filed on Mar. 18, 2020.
Prior Publication US 2021/0290692 A1, Sep. 23, 2021
Int. Cl. A61K 35/60 (2006.01); A61K 9/00 (2006.01); A61K 47/22 (2006.01)

CPC A61K 35/60 (2013.01) [A61K 9/006 (2013.01); A61K 47/22 (2013.01)]

30 Claims

1. A method of substantially minimizing a respiratory illness in an individual subject in need thereof, the method comprising intra-orally administering to the subject an antiviral formulation comprising an effective amount of a free fatty acid (FFA) mixture,

wherein the FFA mixture comprises at least two fatty acids selected from the group consisting of myristic acid, palmitic acid, stearic acid, palmitoleic acid, cis-vaccenic acid, oleic acid, gadoleic acid, gondoic acid, erucic acid, cetoleic acid, linoleic acid, α-linolenic acid, moroctic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),

wherein the amount of the FFA mixture is from about 0.1 to about 20% (v/v),

wherein the respiratory illness is caused by a coronavirus selected from the group consisting of human coronavirus 229E (hCoV-229E) and the SARS-COV-2.